

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

PAR PHARMACEUTICAL, INC.,

Petitioner

v.

HORIZON THERAPEUTICS, LLC,

Patent Owner

---

Case IPR2017-01767

Patent 9,254,278

---

**PATENT OWNER'S UPDATED EXHIBIT LIST**

Pursuant to 37 C.F.R. § 42.63 (e), the Patent Owner hereby provides an updated exhibit list:

Exhibit No.	Description
2001	<i>RESERVED.</i>
2002	Notice of Allowance dated December 23, 2015, Prosecution History of U.S. Patent No. Patent 9,254,278.
2003	Dixon <i>et al.</i> , “Intercurrent Illness in Inborn Errors of Intermediary Metabolism, 67 <i>Archives of Disease in Childhood</i> , 1387-1391 (1992) (“Dixon”).
2004	Rani H. Singh, <i>et al.</i> , “Nutritional Management of Urea Cycle Disorders,” <i>Crit. Care. Clin.</i> 21:S27-35 (2005). (“Singh”).
2005	Portion of Par Pharmaceutical, Inc.’s Initial Invalidation Contentions and Non-Infringement Contentions for U.S. Pat. Nos. 8,404,215 and 8,642,012 (pgs. 16-22), <i>Hyperion Therapeutics, Inc. v. Par Pharmaceutical, Inc.</i> , C.A. No. 2:14-cv-00384 (JRG)(RSP) (E.D. Tex.)
2006	Declaration of Dr. Gregory M. Enns, M.D.
2007	Curriculum <i>vitae</i> of Dr. Gregory M. Enns, M.D.
2008	Ari Auron, Patrick D. Brophy, “Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment,” <i>Pediatric Nephrology</i> , 27:207-22 (2012). (“Auron”).
2009	Mark L. Batshaw, <i>et al.</i> , “Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,” <i>J. Pediatrics</i> , 38:S46-S55 (2001). (“Batshaw”).
2010	Nancy E. Maestri, <i>et al.</i> , “Prospective Treatment of Urea Cycle Disorders,” <i>J. of Pediatrics</i> , 119:923-28, no. 6 (1991). (“Maestri”).

<b>2011</b>	Nancy E. Maestri, <i>et al.</i> , “Plasma Glutamine Concentration: A Guide in the Management of Urea Cycle Disorders,” <i>J. Pediatrics</i> , 121:259–61, no. 2 (1992). (“Maestri 1992”).
<b>2012</b>	U.S. Patent Publication 2012/0022157 A1, filed August 27, 2009, published January 26, 2012. (“157 App”).
<b>2013</b>	Mendel Tuchman & Mark L. Batshaw, “Management of Inherited Disorders of Ureagenesis,” <i>The Endocrinologist</i> 12:99–109, no. 2 (2002). (“Tuchman”).
<b>2014</b>	Guoyao Wu, “Amino Acids: Metabolism, Functions, and Nutrition,” <i>Amino Acids</i> 37:1–17 (2009). (“Wu”).
<b>2015</b>	Alexander Broomfield & Stephen Grunewald, “How to use Serum Ammonia,” <i>Archives of Disease in Childhood—Education and Practice</i> 97:72–77 (2012). (“Broomfield”).
<b>2016</b>	Fumino Endo, <i>et al.</i> , “Clinical Manifestations of Inborn Errors of the Urea Cycle and Related Metabolic Disorders During Childhood,” <i>J. Nutrition</i> 134:1605S–09S (2004). (“Endo”).
<b>2017</b>	Gregory M. Enns, “Nitrogen Sparing Therapy Revisited 2009,” <i>Molecular Genetics and Metabolism</i> 100:S65–S71 (2010). (“Enns 2010”).
<b>2018</b>	Takhar Kasumov, <i>et al.</i> , “New Secondary Metabolites of Phenylbutyrate in Humans and Rats,” <i>Drug Metabolism and Disposition</i> , 32:10–19 (2004) (“Kasumov”).
<b>2019</b>	Johannes Häberle, <i>et al.</i> , “Suggested Guidelines for the Diagnosis and Management of Urea Cycle Disorders,” <i>Orphanet J. Rare Diseases</i> , 7:32, 1–30 (2012). (“Häberle”).
<b>2020</b>	Johannes Häberle, “Clinical Practice: The Management of Hyperammonemia,” <i>Eur. J. of Pediatrics</i> 170:21–34 (2011). (“Häberle Clinical”).
<b>2021</b>	J.V. Leonard & A. A. M. Morris, “Urea Cycle Disorders,” <i>Seminars in Neonatology</i> 7:27–35 (2002). (“Leonard 2002”).

<b>2022</b>	Ann-Kaisa Niemi & Gregory M. Enns, “Sodium Phenylacetate and Sodium Benzoate in the Treatment of Neonatal Hyperammonemia,” <i>NeoReviews</i> , 7:e486–e95, no. 9 (2006). (“Niemi”).
<b>2023</b>	Marshall Summar & Mendel Tuchman, “Proceedings of a Consensus Conference for the Management of Patients with Urea Cycle Disorders,” <i>J. Pediatrics</i> , 138:S6–S10 (2001). (“Summar”).
<b>2024</b>	Saul W. Brusilow & Nancy E. Maestri, “Urea Cycle Disorders: Diagnosis, Pathophysiology, and Therapy,” <i>Advances in Pediatrics</i> 43:127–70 (1996). (“Brusilow 1996”).
<b>2025</b>	Colloquium, “Consensus Statement from a Conference for the Management of Patients with Urea Cycle Disorders,” <i>J. Pediatrics</i> , Supplement 1, 138:S1–S5 (2001). (“Consensus”).
<b>2026</b>	“Specialties of Genetics,” <i>Am. Board of Medical Genetics and Genomics</i> (last accessed Jan. 17, 2017), <a href="http://abmgg.org/pages/training_specialties.shtml">http://abmgg.org/pages/training_specialties.shtml</a> . (“ABMGG”).
<b>2027</b>	“About Us,” <i>Urea Cycle Disorders Consortium</i> (last accessed Oct. 25, 2017), <a href="https://www.rarediseasesnetwork.org/cms/ucdc/About-Us">https://www.rarediseasesnetwork.org/cms/ucdc/About-Us</a> .
<b>2028</b>	Gregory M. Enns, <i>et al.</i> , “Survival After Treatment with Phenylacetate and Benzoate for Urea-Cycle Disorders,” <i>The New England Journal of Medicine</i> 356:2282–92 (2007). (“Enns”).
<b>2029</b>	Gregory M. Enns & Tina M. Cowan, “Hyperammonemia,” in <i>Signs and Symptoms of Genetic Conditions: A Handbook</i> , ch. 18, 261–279 (Louanne Hudgins <i>et al.</i> , eds., 2014). (“Enns 2014”).
<b>2030</b>	Michael Msall, <i>et al.</i> , “Neurologic Outcome in Children with Inborn Errors of Urea Synthesis,” <i>The New England Journal of Medicine</i> 310:1500–1505 (1984). (“Msall”).
<b>2031</b>	B.D. Cheson, <i>et al.</i> , “Novel Therapeutic Agents for the Treatment of Myelodysplastic Syndromes,” in <i>Seminars in Oncology</i> , 27:560–77, no. 5 (John W. Yarbro, <i>et al.</i> eds., 2000). (“Cheson”).

<b>2032</b>	Fernando Scaglia, <i>et al.</i> , “Effect of Alternative Pathway Therapy on Branched Chain Amino Acid Metabolism in Urea Cycle Disorder Patients,” <i>Molecular Genetics and Metabolism, Supplement 1</i> , 81:S79-S85 (2004). (“Scaglia”).
<b>2033</b>	Saul W. Brusilow & Arthur L. Horwich, “Urea Cycle Enzymes,” in <i>The Online Metabolic and Molecular Bases of Inherited Disease</i> , Ch. 85, pp. 1–89 (David Valle et al. eds., 2015). (“Brusilow Online”).
<b>2034</b>	Marshall Summar, “Current Strategies for the Management of Neonatal Urea Cycle Disorders,” <i>J. Pediatrics</i> 138:S30–S39 (2001). (“Summar 2001”).
<b>2035</b>	Marshall L. Summar, <i>et al.</i> , “The Incidence of Urea Cycle Disorders,” <i>Molecular Genetics and Metabolism</i> 110:179–180 (2013). (“Summar 2013”).
<b>2036</b>	Marshall L. Summar, <i>et al.</i> , “Diagnosis, Symptoms, Frequency and Mortality of 260 Patients with Urea Cycle Disorders from a 21-Year, Multicentre Study of Acute Hyperammonaemic Episodes,” <i>Acta Paediatrica</i> 97:1420–25 (2008). (“Summar 2008”).
<b>2037</b>	Bridget Wilcken, “Problems in the Management of Urea Cycle Disorders,” <i>Molecular Genetics and Metabolism</i> 81:S86–S91 (2004). (“Wilcken”).
<b>2038</b>	Information About FDA-Approved Drug, Buphenyl, <a href="http://www.accessdata.fda.gov/scripts/cder/daf/">http://www.accessdata.fda.gov/scripts/cder/daf/</a> (search Drug Name, Active Ingredient, or Application Number field for “020572”, last accessed Feb. 9, 2017)
<b>2039</b>	Gregory M. Enns, “Neurologic Damage and Neurocognitive Dysfunction in Urea Cycle Disorders,” <i>Seminars in Pediatric Neurology</i> , 15:132-139 (2008). (“Enns 2008”).
<b>2040</b>	Ravicti® product insert, <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203284s005lbl.pdf</a> . (“Ravicti Label”).
<b>2041</b>	<i>RESERVED for Declaration of Robert F. Green In Response to Petitioner’s Objections to Evidence.</i>

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.